In an unprecedented move, John Hubbard, Ph.D., senior VP and worldwide head of development operations for Pfizer, announced the strategic partnering with two CROs, ICON and Parexel, as preferred clinical trial outsourcing providers. Hubbard sat down with me to discuss how the two-partner model evolved and how it is going to help spur innovation at the pharma giant.
Clinical Trials In Russia
The Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (Roszdravnadzor) and the Ministry of Health and Social Development of the Russian Federation (MoH) approved 492 new clinical trials of all types including local and bioequivalence studies during 2010, demonstrating a 15% decrease from the prior year's figure.
Excellence In Biomarkers
Biomarkers of disease are assuming an ever increasing role in the discovery and development of drugs. ICON has long recognized their importance in all phases of the development process and has built significant expertise in biomarker development and analysis.
Wallet Package Technology
The wallet package is an effective marketing tool and a growing number of pharmaceutical companies are following the trend towards packaging their blister cards in wallet packs.
Xcellerate Clinical Trial Optimization
Xcellerate helps ensure more cost-effective and timely clinical trials. Providing cutting edge site and investigator selection tools, clinical trial scenario planning, forecasting and resource management, Xcellerate can help you achieve a better return on your clinical investment.